rethinkTHC Search
Menu
Study breakdown

A Comprehensive Review of CBD's Effects on Brain Function Found Promise for Multiple Conditions but Called for Better Regulation

ReviewModerate evidence
The takeaway

CBD shows potential for managing epilepsy, psychosis, anxiety, pain, and inflammation, with emerging evidence for effects on sleep, motor control, and cognition, but products remain largely unregulated and quality and safety standards are lacking.

CBD consumers, neurologists, psychiatrists, regulatory officials, health researchers.

CBD products remain largely unregulated despite widespread therapeutic claims

What the researchers found

CBD has documented therapeutic effects for epileptic seizures, psychosis, anxiety, neuropathic pain, and inflammation. Emerging evidence suggests effects on sleep, motor control, cognition, and memory. CBD influences brain function through multiple mechanisms beyond the endocannabinoid system. Current products do not meet most food safety authority standards for dietary supplements.

Why it matters

CBD has become one of the most popular wellness products globally, but there is a stark gap between consumer interest and regulatory oversight. This review maps what is actually known versus what is marketed.

The numbers in context

No specific quantitative outcomes. Review covers epilepsy, Alzheimer's, Huntington's, Parkinson's, psychosis, anxiety, depression, substance use disorders, sleep, motor control, and cognition.

How the study worked

Comprehensive narrative review synthesizing evidence on CBD's biomolecular properties, mechanisms of action, effects on neurological and mental disorders, behavioral effects, and regulatory considerations.

What this study cannot tell us

Narrative review without systematic methodology. Many covered topics have limited human evidence. Cannot address all CBD product variations and formulations. Regulatory landscape varies by country.

How to read the evidence

Comprehensive narrative review covering multiple conditions. Evidence quality varies from strong (epilepsy) to preliminary (cognition).

When this study was published

Published in 2023.

The bigger picture

The disconnect between CBD's commercial availability and its regulatory status creates a situation where millions of people use products with unverified quality, inconsistent dosing, and uncertain safety. This review argues for responsible research and regulation.

Questions still open

  • Will regulatory frameworks catch up with CBD product proliferation?
  • Which of CBD's many proposed mechanisms is most clinically relevant?

Common questions

What conditions does CBD actually help with?
The strongest evidence supports CBD for epileptic seizures (FDA-approved). There is also meaningful evidence for psychosis, anxiety, and neuropathic pain. Evidence for cognition, sleep, and neurodegenerative diseases is emerging but preliminary.
Are CBD products safe?
Most CBD products do not meet food safety authority standards. Product quality, consistency, and accurate labeling remain significant concerns in the largely unregulated market.

Read the original research

Cannabidiol and brain function: current knowledge and future perspectives.

Frontiers in pharmacology, 14, 1328885

Citation

Schouten, Moniek; Dalle, Sebastiaan; Mantini, Dante; Koppo, Katrien. (2023). Cannabidiol and brain function: current knowledge and future perspectives.. Frontiers in pharmacology, 14, 1328885. https://doi.org/10.3389/fphar.2023.1328885

Explore the wider topic